中文名：AZ876
英文名：AZ876
純度：Moligand?，≥99%
貨號：A413448
Cas號：898800-26-5
存儲溫度：-20°C儲存
運輸條件：超低溫運輸
產品介紹：
Information
AZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.
Targets
LXRα ; LXRβ 0.007 μM(Ki); 0.011 μM(Ki)
In vitro
In binding assays, AZ876 is 25-fold and 2.5-fold more potent than GW3965 on human (h)LXRα and hLXRβ respectively. In reporter transactivation assays, AZ876 is 196-fold and fivefold more potent than GW3965 on hLXRα and hLXRβ respectively. AZ876 is also more potent than GW3965 on mouse (m)LXRα (248-fold) and mLXRβ (10.5-fold). AZ876 is four- to sevenfold more potent than GW3965 on the expression of ABCA1 mRNA in hamster and human blood PMN cells. AZ876 is highly selective with respect to other nuclear hormone receptors, including retinoid X receptor, farnesoid X receptor, thyroid hormone receptor (TR)α or TRβ, when tested in agonist mode in fluorescence resonance energy transfer assays.
In vivo
AZ876 is a dual partial LXR agonist that has been shown to reduce atherosclerosis in mice without affecting liver or plasma triglyceride levels when administered in low dose. Chronic administration of the LXR agonist AZ876 attenuates pathological cardiac hypertrophy in a murine model of chronic pressure overload without altering systemic blood pressure, implicating heart-specific effects. AZ876 treatment diminishes myocardial fibrosis and suppresses induction of profibrotic gene expression.
查看阿拉丁官網(wǎng)此產品相關對應頁面：https://www.aladdin-e.com/zh_cn/A413448.html
關鍵字： 2-tert-butyl-1,1-dioxo-5-phenyl-4-(4-piperidin-1-ylanilino)-1,2-thiazol-3-one ; AZ12260493 ; AZ 87
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代碼：688179），專注于科研試劑的研發(fā)、生產和銷售，已陸續(xù)建立多個工廠和研發(fā)中心。作為領軍企業(yè)，阿拉丁始終堅持質量第一，連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產品品種超過7萬種，SKU總數(shù)超過46萬，產品線涵蓋了化學試劑、生化試劑、藥靶配體、蛋白質和抗體等多個領域，是國內少數(shù)化學試劑到生物試劑全面發(fā)展的國產試劑品牌，產品同步發(fā)布在我們國內外電商平臺。